• Health Canada cleared Palisade Bio’s clinical trial application for its global Phase 2b ASCENTRA-UC study of oral PALI-2108.
• Decision enables Canadian site activation, supporting enrollment of about 204 patients with moderate-to-severe ulcerative colitis.
• Primary efficacy data from the 12-week induction phase is expected in 2H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230845PRIMZONEFULLFEED9832264) on September 23, 2026, and is solely responsible for the information contained therein.